Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.
Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.
Verdant builds AI-powered Smart Sprayers that weed, thin, fertilize & deliver nutrients at millimeter level.
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Stemson Therapeutics is a pre-clinical stage cell therapy company.
BioPhero is a pioneer in providing low-cost bio-based pheromones for pest management.
X-37 is a pharmaceutical discovery and development company
Macromoltek does computational drug discovery for pharma companies, focusing on antibodies for therapeutics and diagnostics.
DCVC Bio has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
DCVC Bio's top investment sectors include Biotechnology, Life Science, Biopharma, Therapeutics, Artificial Intelligence (AI). The firm invests across 14 different industry categories.
Among tracked funding rounds, Verdant Robotics, Inc. received $46.5M in a Series A round. DCVC Bio's total known invested capital is $2.6B.
DCVC Bio's average investment size is $64.0M across its portfolio of 56 companies.
Recent DCVC Bio portfolio additions include Empirico, Novome Biotechnologies, Verdant Robotics, Inc., Creyon Bio, Stemson Therapeutics. These companies were founded in 2020 or later.